Tech Company Financing Transactions

RougeTx Funding Round

RougeTx closed a $58 million Series A funding round on 10/6/2026. Investors included Angelini Ventures, BioGeneration Ventures and European Investment Bank.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Gooimeer 2-35
Naarden, 1411 DC
The Netherlands

Phone

Undisclosed

Website

www.rougetx.com

Email Address

[email protected]

Overview

Developing a new class of therapies targeting pericyte-detachment to treat vascular disease. Our vision is to become the leading company developing pericyte-directed therapies for vascular and microvascular disease. RougeTx is a biotechnology company focused on targeting pericytes, a critical but underexplored cell type responsible for maintaining vascular structure and function.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chairman

Sandra Glucksmann

        

Chief Executive Officer

Andrew Lightfoot

        

Co-Founder

Franck Lebrin

        

VP - Operations

Nikki D'Arcy

        

Browse more venture capital transactions:

Prev: 10/6/2026: Capitolis venture capital transaction
Next: 10/6/2026: Sensible Biotechnologies venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to document tech company VC transactions. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary